Dydrogesterone
Dydrogesterone has been studied in 22 papers since 2019: 5 observational studies in people, 15 reviews; 14 in the past year. It is an approved medicine. The newest paper, Nov 7, 2026: “Risk of colorectal cancer and systemic menopausal hormone therapies: a Finnish cohort study”.
4 new papers in 30 daysSee all 29 papers on dydrogesterone
At a glance
The findings reach people, from one lab or study. 4 independent labs in 3 countries; 30 trials, 1 about aging, 10 with no results posted.
“and lowest for dydrogesterone (1.24, 1.03 to 1.48)”
None of its findings points the other way.
- 4 independent labs in 3 countries
- 30 trials, 1 about aging, 10 with no results posted
- Funders: Akdeniz University and others
- 1 of 8 findings with company ties
- 6 of 30 trials sponsored by its developers
- Humans5
What did studies of dydrogesterone find?
6Studies of dydrogesterone measured 6 outcomes, among them senescence marker expression, cell migration and FoxM1 expression.
Senescence marker expression
no changein human cells1
1 study
Senescence marker expression
no changein human cells1
Dydrogesterone showed no clear effect on senescence marker expression in human cells (Cells from women with recurrent pregnancy loss; DIO2 and β-GAL readouts).
“neither treatment significantly reduced DIO2 or β-GAL expression.”
CellsCells from women with recurrent pregnancy loss; DIO2 and β-GAL readoutsdecidual cellfemales
Decidual senescence in recurrent pregnancy loss: forkhead box M1-targeted progesterone treatment
Reproductive biomedicine online
Cell migration
upin human cells1
1 study
Cell migration
upin human cells1
Dydrogesterone increases cell migration in human cells (Co-culture with decidual cells from women with recurrent pregnancy loss).
“MPA and DYD did not affect spheroid expansion in the RPL group but increased cell migration (p=0.009 and p<0.001, respectively)”
CellsCo-culture with decidual cells from women with recurrent pregnancy lossAC-1M88 trophoblast-like cell co-culture
Decidual senescence in recurrent pregnancy loss: forkhead box M1-targeted progesterone treatment
Reproductive biomedicine online
FoxM1 expression
upin human cells1
1 study
FoxM1 expression
upin human cells1
Dydrogesterone increases FoxM1 expression in human cells (Cells from women with recurrent pregnancy loss).
“MPA and DYD restored FOXM1 expression and improved decidual function, but did not reverse senescence marker expression.”
CellsCells from women with recurrent pregnancy lossdecidual cellfemales
Decidual senescence in recurrent pregnancy loss: forkhead box M1-targeted progesterone treatment
Reproductive biomedicine online
Maternal complications and congenital anomalies
no changein humans1
1 study
Maternal complications and congenital anomalies
no changein humans1
Dydrogesterone showed no clear effect on maternal complications and congenital anomalies in humans.
“No maternal complications or congenital anomalies could be linked to dydrogesterone usage during ARTs or during early pregnancy to prevent recurrent miscarriages.”
Reviewduring assisted reproductive techniques or early pregnancy to prevent recurrent miscarriages
Dydrogesterone after 60 years: a glance at the safety profile
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Common adverse events
upin humans1
1 study
Common adverse events
upin humans1
Dydrogesterone increases common adverse events in humans.
“However, other common AEs, such as headache, dizziness, abdominal pain, flatulence, and nausea, occurred more frequently with dydrogesterone.”
Reviewfemales
Dydrogesterone after 60 years: a glance at the safety profile
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Vagina-related adverse events
downin humans1
1 study
Vagina-related adverse events
downin humans1
Dydrogesterone decreases vagina-related adverse events in humans (luteal phase support during assisted reproductive techniques).
“Vagina-related AEs, such as bleeding, discharge, irritation, and difficult coitus, occurred less frequently with dydrogesterone”
Reviewluteal phase support during assisted reproductive techniquesvaginafemales
Dydrogesterone after 60 years: a glance at the safety profile
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
What is dydrogesterone linked with?
3Studies link dydrogesterone with 3 measures: breast cancer, colorectal cancer and venous thromboembolism.
Breast cancer
downin humans1upin humans1
2 studies
Breast cancer
downin humans1upin humans1
Dydrogesterone is linked with a higher risk of breast cancer in humans (combined progestogen therapy, compared with never use) (odds ratio 1.24 (95% CI 1.03 to 1.48)).
“and lowest for dydrogesterone (1.24, 1.03 to 1.48)”
Humanscombined progestogen therapy, compared with never usefemalesn = 457,498
BMJ (Clinical research ed.)
Dydrogesterone lowers the risk of breast cancer in estrogen-progestogen MHT compared to other combined MHT regimens.
“Oestrogen-only MHT and oestrogen-progestogen MHT containing micronized progesterone or dydrogesterone are associated with lower breast cancer risk compared to other combined MHT regimens.”
Reviewin estrogen-progestogen MHT compared to other combined MHT regimensbreastfemales
Menopausal hormone therapy and breast cancer risk
Best practice & research. Clinical endocrinology & metabolism
Colorectal cancer
downin humans1
1 study
Colorectal cancer
downin humans1
Dydrogesterone is associated with colorectal cancer in humans (31–36% lower CRC risk).
“Dydrogesterone EPT tended to confer 31–36% lower CRC risk than EPTs containing norethisterone or medroxyprogesterone acetate.”
HumansCompared with estrogen-progestogen therapies containing norethisterone or medroxyprogesterone acetateComponent of estrogen-progestogen therapyfemales
Risk of colorectal cancer and systemic menopausal hormone therapies: a Finnish cohort study
Maturitas
Venous thromboembolism
downin humans1
1 study
Venous thromboembolism
downin humans1
Dydrogesterone lowers the risk of venous thromboembolism in humans (compared with other progestogens).
“dydrogesterone may confer advantages in terms of venous thromboembolism and breast cancer risk”
Reviewcompared with other progestogens
Literature review of estradiol/dydrogesterone in perimenopausal and postmenopausal women
Climacteric : the journal of the International Menopause Society
Has dydrogesterone been tested in people?
1 of 30 about agingYes: 5 observational studies in people have been published, and 30 trials are registered.
About aging
Approved
Discontinued
Every condition in trials
Phase 4Completed5 trials
Phase 4Completed5 trials
Gynatresia
Phase 4Status unknown2 trials
Phase 4Completed1 trial
Phase 4Completed1 trial
Phase 4Completed1 trial
All 19Fewer
Stopped
NCT03858049TerminatedInfertility
The trend in LPS treatment tends to increase the dosage of progesterone in FET-HRT, this study was designed 5 years ago.
Trial sponsors
Company1 trialPhase 4172 people
Company1 trialPhase 4135 people
Company3 trialsPhase 32,175 people
2 trialsPhase 4180 people
Peking Union Medical College Hospital
2 trialsPhase 4180 people
Universitair Ziekenhuis Brussel
2 trialsPhase 4180 people
Shanghai First Maternity and Infant Hospital
1 trialPhase 4500 people
1 trialPhase 4186 people